Prevalence of primary Sjögren's syndrome in patients undergoing evaluation for pulmonary arterial hypertension

PLoS One. 2018 May 15;13(5):e0197297. doi: 10.1371/journal.pone.0197297. eCollection 2018.

Abstract

Background: The prevalence of pulmonary arterial hypertension (PAH) in primary Sjögren's syndrome (SS) had been reported to be rare. However, recent studies using echocardiography as a screening method showed conflicting results, and the true prevalence is still unclear. Since diagnosing primary SS is difficult because of its heterogeneous nature, a number of patients with primary-SS-associated PAH may be misdiagnosed with idiopathic PAH, losing their chance to undergo immunosuppressive therapy. Therefore, we sought to elucidate the prevalence of primary SS among patients who initially present with PAH.

Methods: From our prospective institutional PAH database, 40 consecutive patients without any obvious cause of PAH at the time of PAH diagnosis were identified. We retrospectively evaluated the prevalence of primary SS diagnosed during or after the initial assessment of PAH.

Results: During the initial assessment, one patient was diagnosed with primary-SS-associated PAH. Among the 25 patients who were initially diagnosed with idiopathic PAH, five were diagnosed with primary SS during their course of the disease. Of the five patients, three had key signs suggesting primary SS and were probably underdiagnosed at the time of initial evaluation. The remaining two patients, who were finally diagnosed with primary SS, did not have any specific signs suggesting primary SS at the time of initial evaluation but showed positive conversion of their autoantibodies during the course of PAH.

Conclusion: The prevalence of primary-SS-associated PAH may be relatively high among patients who undergo initial evaluation for PAH. Furthermore, primary-SS-associated PAH may be underdiagnosed with routine evaluation for the primary cause of PAH. Clinicians should pay specific attention and carefully evaluate the possibility of primary SS in patients with PAH.

MeSH terms

  • Adult
  • Female
  • Humans
  • Hypertension, Pulmonary / diagnosis*
  • Hypertension, Pulmonary / epidemiology*
  • Hypertension, Pulmonary / etiology
  • Hypertension, Pulmonary / therapy
  • Immunosuppression Therapy
  • Male
  • Middle Aged
  • Prevalence
  • Prospective Studies
  • Retrospective Studies
  • Severity of Illness Index
  • Sjogren's Syndrome / complications
  • Sjogren's Syndrome / diagnosis*
  • Sjogren's Syndrome / epidemiology*
  • Sjogren's Syndrome / therapy
  • Young Adult

Grants and funding

The authors received no specific funding for this work. The authors would like to disclose the following: Masaru Hatano received endowment from Bayer, GlaxoSmithKline, and Nippon Shinyaku; and honoraria from Bayer, Pfizer, Actelion, and Nippon Shinyaku. Keishi Fujio may benefit from a patent belonging to Chugai Pharmaceuticals (B cell activation inhibitor, and therapeutic agent for autoimmune diseases: PCT/JP2015/065466). This does not alter our adherence to PLOS ONE policies on sharing data and materials. Keishi Fujio received research grants from Chugai Pharmaceuticals, Bristol-Myers Squibb, AbbVie, Astellas, Mitsubishi-Tanabe, Eisai, Daiichi-Sankyo, Pfizer, and Takeda; and received travel grants and honoraria from Chugai Pharmaceuticals, Bristol-Myers Squibb, Daiichi-Sankyo, Mitsubishi-Tanabe, Pfizer, Ayumi, Eisai, AbbVie, UCB, Janssen, Taisho Toyama, Aurinia, Astellas, Eli-Lilly, and Takeda. Masafumi Watanabe received endowment from Takeda. Kazuhiko Yamamoto received honoraria from AbbVie, Astellas Pharma, Ayumi Pharmaceutical, Bristol-Myers Squibb, Chugai Pharmaceutical, Eisai, Janssen Pharmaceutical, Mitsubishi Tanabe Pharma, Ono Pharmaceutical, Takeda Pharmaceutical, and UCB Japan.